Jefferies Raises Price Target On Quest Diagnostics (DGX) to $66

Jefferies raised its price target on Hold-rated Quest Diagnostics (NYSE: DGX) from $61 to $66 following Q4 results.

The firm comments, "Good Q4 results along with prospects for improved volumes and expanded margins have given investors a shot of confidence in DGX and other healthcare service stocks. Looking ahead, though, we expect the momentum in DGX's stock price to taper a bit as we wait for (1) the announcement of a new CEO, (2) further evidence of improved utilization trends and (3) increased reimbursement visibility."

For an analyst ratings summary and ratings history on Quest Diagnostics click here. For more ratings news on Quest Diagnostics click here.

Shares of Quest Diagnostics closed at $60.55 yesterday, with a 52 week range of $45.13-$61.47.

---

Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• Barclays Maintains an 'Equalweight' on J. C. Penney (JCP); Slashing PT on Disappointing Results
• Canaccord Genuity Reiterates a 'Buy' on Analog Devices (ADI); Delivering Upside
• Nomura Securities Raises PT and Estimates on PetSmart (PETM) After Good Q1

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter